Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fuzheng Jiebiao formula (扶正解表方) is a Traditional Chinese Medicine (TCM) herbal preparation used primarily for the treatment of viral respiratory infections, including COVID-19 (SARS-CoV-2) and influenza. The formula is based on the TCM therapeutic principle of 'strengthening the body's resistance to eliminate pathogenic factors' (Fuzheng Jiebiao), which involves combining tonifying herbs to support the host immune system with diaporetic or exterior-relieving herbs to address acute symptoms such as fever, cough, and malaise. While specific compositions may vary slightly by clinical protocol, common constituents often include *Astragalus membranaceus* (Huangqi), *Saposhnikovia divaricate* (Fangfeng), *Lonicera japonica* (Jinyinhua), and *Forsythia suspensa* (Lianqiao). It has been evaluated in various clinical trials in China for its potential to reduce viral shedding duration, alleviate clinical symptoms, and prevent the progression of mild respiratory infections to severe pneumonia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fuzheng jiebiao formula.